2026-04-17T06:33:49Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/95232024-12-13T09:40:10Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
López Jaime, Francisco José
author
Benítez Hidalgo, Olga
author
Díaz Jordán, Bolívar Luis
author
Montaño, Adrián
author
Coll, Julia
author
Quintana Paris, Laura
2023-11-08T10:19:34Z
2023-11-08T10:19:34Z
2023-05-12T11:21:26Z2023-05-12T11:21:26Z2023
http://hdl.handle.net/11351/9523
Hemophilia A; Inhibitor; Joint healthHemofília A; Inhibidor; Salut articularHemofilia A; Inhibidor; Salud articularIntroduction
Prophylaxis with emicizumab, a bispecific monoclonal antibody that mimics FVIII function, has shown encouraging results in clinical trials in terms of efficacy and safety. However, current experience is limited, and many areas of concern to clinicians have yet to be reviewed.
Areas covered
This paper reviews the experience of hemophilia A patients treated with emicizumab based on the results of clinical trials and real-life studies. The authors place special emphasis on issues such as the management of these patients in situations of hemorrhage and/or surgical interventions, joint health or laboratory monitoring.
Expert opinion
Treatment with emicizumab has been shown to improve joint health and reduce bleeding, of particular interest to patients with inhibitors and high bleeding rates. However, there are still concerns about its administration in neonates and previously untreated patients due to limited reported experience. Laboratory monitoring is not strictly necessary due to the stable pharmacokinetics emicizumab has been shown to exhibit, however, tests that globally assess hemostasis may be useful especially in cases of bleeding or surgery. The authors are also of the opinion that prophylaxis before minor surgery is not necessary and that major surgeries can be safely performed with additional prophylactic coagulation factor.This work was supported by European Union – Next Generation EU through a Margarita Salas contract of the University of Salamanca.
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess
Hemofília - Tractament
Immunoglobulines - Ús terapèutic
DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Blood Coagulation Disorders::Blood Coagulation Disorders, Inherited::Hemophilia A
Other subheadings::Other subheadings::Other subheadings::/drug therapy
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Bispecific
Other subheadings::Other subheadings::/therapeutic use
ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::trastornos de la coagulación sanguínea::trastornos de la coagulación sanguínea hereditarios::hemofilia A
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos biespecíficos
Otros calificadores::Otros calificadores::/uso terapéutico
Expert opinion paper on the treatment of hemophilia A with emicizumab
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion